Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Remimazolam (RMZ) is a new and ultra‐fast‐acting, short‐duration intravenous benzodiazepine, a drug class associated with abuse potential. This trial was designed to compare the abuse potential of remimazolam with placebo and midazolam (MDZ), a well‐characterized member of the same pharmacological class in healthy, recreational drug users 18‐55 years‐of‐age, who demonstrated good drug tolerance and were able to discriminate between midazolam and placebo. At equipotent intravenous doses selected to produce effects ranging from mild/moderate to relatively strong sedation without loss of consciousness (RMZ: 5, 10 mg versus MDZ: 2.5, 5 mg), peak scores (E max or E min, respectively) for drug liking, good/bad/any effects, and sedation (drowsiness and relaxation) were significantly greater than placebo for both active drugs and were broadly comparable between RMZ and MDZ. In contrast, areas under the effect‐time curves (TA_AUE) were notably lower for RMZ versus MDZ, particularly for measures of good and any effects, reflecting the shorter duration of action and consistent with the more rapid observed plasma clearance for RMZ versus MDZ and the lack of an active RMZ metabolite. Scores for willingness to take drug again were also lower for RMZ versus MDZ, but not significantly so. We concluded that the abuse potential of RMZ is comparable to or lower than that of MDZ, a drug known to have a low potential for intravenous abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017) · BMJ · doi:10.1136/bmj.j760 · Cited by 534
The effects of scopolamine on working memory in healthy young volunteers
Rusted, J. M., & Warburton, D. M. (1988) · Psychopharmacology · doi:10.1007/bf00177553 · Cited by 116
Cited by
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
Remimazolam: pharmacological characteristics and clinical applications in anesthesiology
Kim, K. M. (2022) · Anesthesia and Pain Medicine · doi:10.17085/apm.21115 · Cited by 257
Remimazolam: a review in procedural sedation
Lee, A., & Shirley, M. (2021) · Drugs · doi:10.1007/s40265-021-01544-8 · Cited by 194
Induction and maintenance of procedural sedation in adults: focus on remimazolam injection
Chen, W., Chen, S., & Huang, Y. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901575 · Cited by 25
“Therefore, it is concluded that remimazolam has a comparable or lower abuse potential compared to midazolam, which is a drug known to be with a low potential for intravenous abuse [90].”
Background
Metadata
- Authors
- Schippers, F., Pesic, M., Saunders, R., Borkett, K., Searle, S., Webster, L., & Stoehr, T.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2020-06-03
- Volume
- 60
- Issue
- 9
- Pages
- 1189-1197
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W3029254733
- Cited by
- 39
- References
- 3
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.